loading page

Prolonged remission in metastatic ano-rectal malignant melanoma with single agent temozolomide
  • +5
  • Anusha Mruthyunjaya Swamy,
  • Deepak Sundriyal,
  • Mayank Kapoor,
  • Mridul Khanna,
  • Ravi Hari Phulware,
  • Kranthi Kumar Jandrasupalli,
  • Ujjawal Kumar Shriwastav,
  • Amit Sehrawat
Anusha Mruthyunjaya Swamy
All India Institute of Medical Sciences Department of Medical Oncology
Author Profile
Deepak Sundriyal
All India Institute of Medical Sciences Department of Medical Oncology
Author Profile
Mayank Kapoor
All India Institute of Medical Sciences Department of Medical Oncology
Author Profile
Mridul Khanna
All India Institute of Medical Sciences Department of Medical Oncology
Author Profile
Ravi Hari Phulware
All India Institute of Medical Sciences - Rishikesh
Author Profile
Kranthi Kumar Jandrasupalli
All India Institute of Medical Sciences - Rishikesh
Author Profile
Ujjawal Kumar Shriwastav
All India Institute of Medical Sciences Department of Medical Oncology

Corresponding Author:drujjawals@gmail.com

Author Profile
Amit Sehrawat
All India Institute of Medical Sciences Department of Medical Oncology
Author Profile

Abstract

With the use of Immune Checkpoint Inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first-line treatment. However, in a resource-limited setting, where access to ICIs and targeted therapies is not feasible, and in patients who fail to tolerate these therapies, chemotherapy continues to remain effective. The median survival and response rates with chemotherapy alone are dismally low. Here, we report a case in which a patient with stage IV anorectal melanoma was able to achieve a complete metabolic response and sustain it for 3 years and continue to do so with the first-line single-agent temozolomide.
27 Jul 2024Submitted to Cancer Reports
29 Jul 2024Submission Checks Completed
29 Jul 2024Assigned to Editor
29 Jul 2024Review(s) Completed, Editorial Evaluation Pending
31 Jul 2024Reviewer(s) Assigned